By Jacob Gronholt-Pedersen and Maggie Fick

Summary:

– Novo and Lilly lower U.S. prices for Wegovy and Zepbound under government programs.

– Shares dip as price cuts hit, but higher volumes expected long-term.

– Starter doses for new obesity drugs may begin at $149 per month.

COPENHAGEN — Shares in Novo Nordisk and Eli Lilly slip ped on Friday after both agreed with the U.S government to lower prices of their blockb us ter GLP-1 weight-loss drug s.

The deal announced on Thursday, covering Novo ‘s Wegovy and Lilly ‘s Zepbound, will reduce monthly prices for U.S. government programmes, including Medicare and Medicaid , and cash payers to between $149 and $350, down from $500 to $1,000.

It also grants them a three-year relief from tariffs.

Near-te

See Full Page